Peak Bio (NASDAQ:PKBO – Get Rating) and Curis (NASDAQ:CRIS – Get Rating) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, profitability, institutional ownership, risk, analyst recommendations, earnings and valuation.
Institutional and Insider Ownership
64.4% of Peak Bio shares are held by institutional investors. Comparatively, 38.7% of Curis shares are held by institutional investors. 19.9% of Peak Bio shares are held by insiders. Comparatively, 6.2% of Curis shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Get Peak Bio alerts:Profitability
This table compares Peak Bio and Curis' net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Peak Bio | N/A | N/A | -1.34% |
| Curis | -566.41% | -82.91% | -42.52% |
Analyst Recommendations
This is a breakdown of current ratings for Peak Bio and Curis, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Peak Bio | 0 | 0 | 1 | 0 | 3.00 |
| Curis | 0 | 1 | 3 | 0 | 2.75 |
Peak Bio presently has a consensus target price of $15.00, indicating a potential upside of 1,899.73%. Curis has a consensus target price of $7.67, indicating a potential upside of 1,004.71%. Given Peak Bio's stronger consensus rating and higher possible upside, equities research analysts clearly believe Peak Bio is more favorable than Curis.
Volatility & Risk
Peak Bio has a beta of -0.6, indicating that its stock price is 160% less volatile than the S&P 500. Comparatively, Curis has a beta of 2.88, indicating that its stock price is 188% more volatile than the S&P 500.
Earnings and Valuation
This table compares Peak Bio and Curis' revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Peak Bio | N/A | N/A | -$490,000.00 | N/A | N/A |
| Curis | $10.65 million | 6.28 | -$45.44 million | ($0.64) | -1.08 |
Peak Bio has higher earnings, but lower revenue than Curis.
Summary
Peak Bio beats Curis on 8 of the 11 factors compared between the two stocks.
About Peak Bio
(Get Rating)
Peak Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of patients with inflammatory, cancer, and rare and specialty diseases. Its lead product candidate is PHP-303, which is in phase 2 clinical study for the treatment of alpha-1 antitrypsin deficiency and acute respiratory distress syndrome. It also develops Trop2 PH1, an antibody-drug-conjugate for solid tumors. The company was founded in 2020 and is headquartered in Palo Alto, California.
About Curis
(Get Rating)
Curis, Inc. engages in the development and commercialization of drug candidates for the treatment of human cancers. Its pipeline includes CUDC-907, CA-4948, CA-170 and CA-327. The CUDC-907 pipeline is an orally available small molecule inhibitor of HDAC and PI3K enzymes. The CA-170 pipeline is an also an orally-available small molecule antagonist of PD-L1 and VISTA immune checkpoints. The company was founded on February 14, 2000 and is headquartered in Lexington, MA.
Receive News & Ratings for Peak Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Peak Bio and related companies with MarketBeat.com's FREE daily email newsletter.